Literature DB >> 9674940

Anticonvulsants and antipsychotics in the treatment of bipolar disorder.

P E Keck1, S L McElroy, S M Strakowski.   

Abstract

A number of recent advances in clinical psychopharmacology regarding anticonvulsant and new antipsychotic medications have important implications with respect to the treatment of patients who have bipolar disorder. The authors reviewed the available literature on the efficacy of the anticonvulsants valproate, carbamazepine, gabapentin, and lamotrigine for the treatment of bipolar disorder. They also reviewed the use of standard and new antipsychotic medications for the treatment of various aspects of the illness. Valproate and carbamazepine have been shown to be effective in the treatment of acute mania in controlled trials. Preliminary data suggest that these agents may differ in their time course of antimanic activity and predictors of response. Neither agent has been extensively studied in controlled trials in bipolar depression or as maintenance therapy, although carbamazepine has received the most systematic study in these areas. Gabapentin and lamotrigine are only now being evaluated in controlled trials in patients who have bipolar disorder. Antipsychotics are commonly used in the treatment of patients with acute mania and as maintenance treatment. However, the use of standard antipsychotics in acute mania is associated with a number of limitations. New antipsychotic agents may possess thymoleptic as well as antipsychotic activity, but they have not been studied in controlled trials in bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674940

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

1.  A 4-year study of lithium intoxication reported to the Czech Toxicological Information Centre.

Authors:  Martina Krenová; Daniela Pelclová
Journal:  Pharm World Sci       Date:  2006-11-17

Review 2.  [Treatment options for bipolar mania].

Authors:  T Attarbaschi; S Kasper
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 4.  Comparative efficacy and tolerability of drug treatments for bipolar disorder.

Authors:  S M Strakowski; M P DelBello; C M Adler
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 5.  Olanzapine: a review of its use in the treatment of bipolar I disorder.

Authors:  N Bhana; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

6.  Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation.

Authors:  Rita Moretti; Paola Torre; Rodolfo M Antonello; Giuseppe Cazzato; Antonio Bava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  The social, psychopathological and consumer context of rate of symptom improvement in acute mania.

Authors:  Jim van Os; Inge van Rossum; Maarten Boomsma; Eduard Vieta; Iris Goetz; Catherine Reed; Josep Maria Haro
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-06-27       Impact factor: 4.328

Review 8.  Avoiding drug-induced switching in patients with bipolar depression.

Authors:  Chantal Henry; Jacques Demotes-Mainard
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Mixed versus manic bipolar disorder: a comparison of demographic, symptomatic, and treatment differences.

Authors:  Nurun N Shah; Patricia M Averill; Andrew Shack
Journal:  Psychiatr Q       Date:  2004

10.  Toxic epidermal necrolysis due to concomitant use of lamotrigine and valproic Acid.

Authors:  Sukhjot Kaur; Alka Dogra
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.